Summary by Moomoo AI
On February 23, 2024, Pfizer Inc. (Pfizer) and its wholly-owned subsidiary Pfizer Investment Enterprises Pte. Ltd. (Pfizer Singapore) filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, depositary shares, purchase contracts, and purchase units. The registration statement allows for the sale of these securities from time to time in one or more offerings. The securities may be offered at fixed prices, prevailing market prices, or negotiated prices, and may be sold through underwriters, dealers, agents, directly to purchasers, or through a combination of these methods. The registration statement also includes provisions for the indemnification of directors and officers, and outlines the potential anti-takeover effects of Pfizer's corporate governance documents and Delaware law. The specific terms of any offering, including the names of any underwriters and the compensation provided to them, will be detailed in future prospectus supplements filed with the SEC.